Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M128,696Revenue (TTM) $M22,474Net Margin (%)33.1Altman Z-Score2.9
Enterprise Value $M126,884EPS (TTM) $9.8Operating Margin %40.7Piotroski F-Score8
P/E(ttm)17.6Beneish M-Score-2.5Pre-tax Margin (%)38.1Higher ROA y-yY
Price/Book4.310-y EBITDA Growth Rate %11.8Quick Ratio3.7Cash flow > EarningsY
Price/Sales5.85-y EBITDA Growth Rate %17.6Current Ratio4.0Lower Leverage y-yY
Price/Free Cash Flow16.1y-y EBITDA Growth Rate %25.1ROA % (ttm)10.2Higher Current Ratio y-yN
Dividend Yield %2.2PEG1.0ROE % (ttm)26.1Less Shares Outstanding y-yY
Payout Ratio %37.0Shares Outstanding M748ROIC % (ttm)27.8Gross Margin Increase y-yY

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNThird Avenue Management 2016-06-30 Buy 0.92%$144.58 - $164.35
($155.39)
$ 171.9711%New holding135,642
AMGNJoel Greenblatt 2016-06-30 Add0.3%$144.58 - $164.35
($155.39)
$ 171.9711%Add 50.26%485,933
AMGNFirst Eagle Investment 2016-06-30 Reduce-0.11%$144.58 - $164.35
($155.39)
$ 171.9711%Reduce -24.17%936,565
AMGNVanguard Health Care Fund 2016-06-30 Reduce-0.02%$144.58 - $164.35
($155.39)
$ 171.9711%Reduce -0.98%5,190,355
AMGNKeeley Asset Management Corp 2016-06-30 Buy 0.01%$144.58 - $164.35
($155.39)
$ 171.9711%New holding1,325
AMGNKen Fisher 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 171.9711%Reduce -9.87%101,573
AMGNMario Gabelli 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 171.9711%Reduce -2.38%36,325
AMGNDodge & Cox 2016-06-30 Reduce$144.58 - $164.35
($155.39)
$ 171.9711%Reduce -5.28%41,257
AMGNFirst Eagle Investment 2016-03-31 Add0.11%$140.9 - $162.33
($148.76)
$ 171.9716%Add 28.98%1,235,154
AMGNJoel Greenblatt 2016-03-31 Add0.08%$140.9 - $162.33
($148.76)
$ 171.9716%Add 16.86%323,405
AMGNVanguard Health Care Fund 2016-03-31 Reduce-0.05%$140.9 - $162.33
($148.76)
$ 171.9716%Reduce -2.91%5,241,755
AMGNKen Fisher 2016-03-31 Reduce-0.01%$140.9 - $162.33
($148.76)
$ 171.9716%Reduce -17.38%112,693
AMGNGeorge Soros 2016-03-31 Sold Out -0.01%$140.9 - $162.33
($148.76)
$ 171.9716%Sold Out0
AMGNMario Gabelli 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 171.9716%Reduce -5.02%37,210
AMGNDodge & Cox 2016-03-31 Reduce$140.9 - $162.33
($148.76)
$ 171.9716%Reduce -6.62%43,557
AMGNRuane Cunniff 2016-03-31 Sold Out $140.9 - $162.33
($148.76)
$ 171.9716%Sold Out0
AMGNJoel Greenblatt 2015-12-31 Reduce-0.18%$141.22 - $164.58
($157.65)
$ 171.979%Reduce -31.85%276,751
AMGNFirst Eagle Investment 2015-12-31 Add0.17%$141.22 - $164.58
($157.65)
$ 171.979%Add 73.61%957,656
AMGNVanguard Health Care Fund 2015-12-31 Reduce-0.05%$141.22 - $164.58
($157.65)
$ 171.979%Reduce -3.25%5,398,985
AMGNGeorge Soros 2015-12-31 Add0.01%$141.22 - $164.58
($157.65)
$ 171.979%Add 109.52%4,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Such Annette LouiseVP, Finance and CAO 2016-08-02Sell3,000$174.59-1.5view
Balachandran MadhavanEVP, Operations 2016-05-04Sell30,000$154.1211.58view
Harper Sean EEVP, Research & Development 2016-04-29Sell21,875$157.998.85view
BALTIMORE DAVIDDirector 2016-04-29Sell3,312$157.219.39view
Bradway Robert AChairman, CEO and President 2016-03-02Sell20,000$146.4817.4view
de Carbonnel FrancoisDirector 2015-08-31Sell5,000$153.8411.78view
Hassan FredDirector 2015-08-19Buy3,010$166.633.2view
PELHAM JUDITH CDirector 2015-07-31Sell5,035$180.4-4.67view
Patton Cynthia MSVP & CCO 2015-06-02Sell4,530$157.069.49view
Balachandran MadhavanEVP, Operations 2015-05-07Sell21,750$157.878.93view

Press Releases about AMGN :

Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Martin Whitman’s Third Avenue Management Purchases 8 Stocks Aug 12 2016 
    Healthcare Dividend Growth Stocks: Part 1 Aug 12 2016 
    Healthcare Dividend Growth Stocks: Part 1 Aug 04 2016 
    Can Novartis Win the Entresto Bet? Aug 03 2016 
    Sam Isaly's Top Investments of the Year Aug 01 2016 
    Daniel Loeb's Third Point 2nd-Quarter 2016 Investor Letter Jul 27 2016 
    5 Attractive Biotechnology Stocks for Healthy Long-term Returns Jun 10 2016 
    John Buckingham Touts Apple, Gilead, Amgen May 11 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 

    More From Other Websites
    What Tidings From the Tetons? Long-Awaited Yellen Speech Today Aug 26 2016
    [$$] Don't Expect an Amgen Breakup Aug 26 2016
    Analyzing Goldman Sachs’s Stock Picks with Growing Dividends Aug 26 2016
    Coverage initiated on Amgen by Gabelli & Co Aug 26 2016
    Mylan offers price plan to help patients but its programs are still short on details Aug 26 2016
    ADXS: Multiple Progresses Have Been Made Aug 25 2016
    Amgen's Shameful Silence Covers Up Reasons for FDA Drug Rejection Aug 25 2016
    Short Sellers Increase Bets in Major Biotechs Aug 25 2016
    Amgen Gets CRL for Secondary Hyperparathyroidism Drug Aug 25 2016
    [$$] FDA Rejects Amgen Hormonal-Imbalance Treatment Aug 24 2016
    Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted... Aug 24 2016
    Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted... Aug 24 2016
    Top trades for the 2nd half: Lending Club, Amgen & more Aug 24 2016
    What Are Analysts’ Recommendations for AbbVie in 2016? Aug 23 2016
    Top trades for the 2nd half: CVS, SQ & more Aug 23 2016
    [$$] Pfizer’s Medivation Deal Latest in Long Line of Similar Acquisitions Aug 22 2016
    [$$] Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions Aug 22 2016
    New Data Add To Understanding Of Repatha® (Evolocumab) In Multiple Patient Populations Aug 22 2016
    AMGEN INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Aug 19 2016
    Biotech Stock Roundup: Vertex Slips on Study Halt, Aurinia Plunges on Lupus Data Aug 17 2016
    Amgen Launches Commercial Office in Hong Kong Aug 11 2016
    HIGHGRADE CLOSE-Five high-grade issuers raise US$9.4bn Aug 10 2016
    US high-grade inches close to record August Aug 10 2016
    In change of tack, UK agency backs Amgen virus-based cancer drug Aug 09 2016
    Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration Aug 02 2016
    Amgen And Advaxis Enter Global Cancer Immunotherapies Collaboration Aug 02 2016
    Amgen tops Street 2Q forecasts Jul 27 2016
    Amgen Reports Second Quarter 2016 Financial Results Jul 27 2016
    Amgen Announces 2016 Third Quarter Dividend Jul 22 2016
    Amgen Announces Webcast Of 2016 Second Quarter Financial Results Jul 22 2016
    Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA Jul 22 2016
    Valeant psoriasis drug's suicide risk hard to assess -FDA Staff Jul 15 2016
    Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan Jul 13 2016
    Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan Jul 13 2016
    Amgen and Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan Jul 13 2016
    European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The... Jul 13 2016
    Lower-cost biotech drug gets thumbs up from FDA panel Jul 12 2016
    Amgen To Discuss Data Supporting Biologics License Application For ABP 501, A Biosimilar Candidate... Jul 12 2016
    FDA Approves First And Only Single Monthly Injection For A PCSK9 Inhibitor Jul 11 2016
    European Commission Approves Extended Indication For Amgen's Kyprolis® (Carfilzomib) For The... Jul 04 2016
    Takeda Revises Collaboration Agreement with Amgen, Returning the Development and Commercialization... Jun 24 2016
    Amgen Sponsors [email protected] Incubator For Life Science Startups Jun 22 2016
    Amgen Appoints Esteban Santos Executive Vice President, Operations Jun 17 2016
    Amgen Announces FDA Advisory Committee Meeting To Review ABP 501, A Biosimilar Candidate To... Jun 13 2016
    Amgen Announces Expiration And Final Results Of Senior Notes Exchange Offers Jun 10 2016
    Analysis - Pfizer's Anacor deal showcases new wave of eczema therapies May 17 2016
    Exclusive - Medivation succumbs to pressure to explore sale: sources May 09 2016
    Sanofi, Amgen cholesterol drugs win UK backing after price cuts May 05 2016
    US stocks hit by health care woes but avoid bigger losses Apr 29 2016
    Amgen posts 1Q sales, profit jumps, raises profit forecasts Apr 28 2016
    Amgen beats Street 1Q forecasts Apr 28 2016
    Breakthrough cholesterol drugs fizzle amid price pushback Apr 20 2016
    Sean Parker sets up $250 million cancer immunotherapy collaboration Apr 12 2016
    FDA approves 1st cheaper version of J&J's top drug Remicade Apr 05 2016
    Factbox - Price hikes shore up revenue for top-selling U.S. drugs Apr 04 2016
    Exclusive - Makers took big price increases on widely used U.S. drugs Apr 04 2016
    US stocks jump after solid March jobs report Apr 01 2016
    Regeneron loses patent dispute over key cholesterol drug Mar 16 2016
    UK cost agency rejects Amgen's virus-based cancer drug Mar 16 2016
    Study: $3B will be wasted on unused portion of cancer drugs Mar 01 2016
    UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016
    UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Feb 08 2016
    Amgen fourth quarter profit tops Street; raises 2016 forecast Jan 28 2016
    Amgen fourth quarter profit tops Street; raises 2016 forecast Jan 28 2016
    Amgen trounces Street views with 39 pct. jump in 4Q profit Jan 28 2016
    Amgen beats Street 4Q forecasts Jan 28 2016
    Amgen reacquires rights to three drugs from Glaxo in 48 countries Dec 14 2015
    Amgen reacquires rights to three drugs from Glaxo in 48 countries Dec 14 2015
    UK cost watchdog turns down Amgen's new cholesterol drug Nov 18 2015
    UK cost watchdog turns down Amgen's new cholesterol drug Nov 18 2015
    Intas Pharma expects U.S. approval for Neulasta biosimilar this year Sep 18 2015
    U.S. SEC drops Onyx insider trading lawsuit against Dubai men Sep 16 2015
    SEC drops Onyx insider trading lawsuit against Dubai men Sep 16 2015
    Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Sep 03 2015
    AstraZeneca reboots psoriasis drug in development deal with Valeant Sep 01 2015
    Amgen profit tops Street view, boosts full-year forecast Jul 30 2015
    Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid Jul 27 2015
    Drugmaker Novartis blocked from selling Neupogen copycat until Sept. 2 Jul 21 2015
    Novartis blocked from selling Neupogen copycat until September Jul 21 2015
    AstraZeneca hit after psoriasis drug linked to suicide fears May 26 2015
    Amgen ends partnership with AstraZeneca on psoriasis drug May 22 2015
    Amgen ends collaboration with AstraZeneca on inflammation drug May 22 2015
    Amgen first to win EU backing for new kind of cholesterol drug May 22 2015
    Amgen cholesterol drug could get EU green light this week May 19 2015
    Under pressure, FDA to hold public meeting on off-label use May 06 2015
    Exclusive - Amgen's new leukemia drug to carry $178,000 price tag Dec 17 2014

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)